Dextromethorphan upregulates osteoblast and osteoclast activity but does not attenuate ovariectomy-induced osteoporosis

Jia Lin Wu, Wei Yuan Tsai, Jian Horng Chen, Chih Shung Wong

Research output: Contribution to journalArticle

Abstract

Aims Study on the in vivo regulatory role of glutamate in osteoblast (OB) and osteoclast (OC) differentiation is less advanced. The present study investigated the effect of dextromethorphan (DXM), an N-methyl-D-aspartate receptors (NMDARs) antagonist, on osteoporosis development. Main methods In order to examine the role of glutamate in bone metabolism, ovariectomized (Ovx) female Wistar rats were injected three times per week for 8 weeks with either saline, or 15 μg/kg of β-estrodiol, or DXM (40 mg/kg) intraperitoneally. Serum samples were collected every two weeks for measuring osteocalcin and C-terminal telopeptide of type I collagen (CTX-1) level. Rats were then sacrificed at week 8 and the femurs harvested for micro-CT scanning and mechanical strength. Key findings In saline-treated group, osteocalcin level significantly lower than that of sham-operated rats at 8 weeks after operation, while CTX-1 levels were not affected. Estrogen treatment, as a positive control, partially inhibited the Ovx-induced reduction of osteocalcin serum level. DXM injection prevented the Ovx-induced reduction of osteocalcin expression and significantly upregulated CTX-1 expression. The micro-CT scan showed that the bone volume density decreased significantly in DXM treated rats compared to the sham-operated rats. In the mechanical strength assay, the maximum failure load for DXM treatment was significantly lower than the other groups. Significance Treatment with DXM upregulated OB and OC markers in Ovx rats, however with a greater effect on the OC marker, and had no significant benefit on bone volume density or bone strength.

Original languageEnglish
Pages (from-to)145-149
Number of pages5
JournalLife Sciences
Volume173
DOIs
Publication statusPublished - Mar 15 2017

Fingerprint

Dextromethorphan
Osteoblasts
Ovariectomy
Osteoclasts
Osteoporosis
Rats
Up-Regulation
Osteocalcin
Bone
Bone Density
Strength of materials
Glutamic Acid
Bone and Bones
Computerized tomography
N-Methyl-D-Aspartate Receptors
Serum
Metabolism
Femur
Wistar Rats
Loads (forces)

Keywords

  • Dextromethorphan
  • Glutamate
  • Osteoblast
  • Osteoclast
  • Osteoporosis

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Dextromethorphan upregulates osteoblast and osteoclast activity but does not attenuate ovariectomy-induced osteoporosis. / Wu, Jia Lin; Tsai, Wei Yuan; Chen, Jian Horng; Wong, Chih Shung.

In: Life Sciences, Vol. 173, 15.03.2017, p. 145-149.

Research output: Contribution to journalArticle

Wu, Jia Lin ; Tsai, Wei Yuan ; Chen, Jian Horng ; Wong, Chih Shung. / Dextromethorphan upregulates osteoblast and osteoclast activity but does not attenuate ovariectomy-induced osteoporosis. In: Life Sciences. 2017 ; Vol. 173. pp. 145-149.
@article{c964b420545a4a5197819263aa306d80,
title = "Dextromethorphan upregulates osteoblast and osteoclast activity but does not attenuate ovariectomy-induced osteoporosis",
abstract = "Aims Study on the in vivo regulatory role of glutamate in osteoblast (OB) and osteoclast (OC) differentiation is less advanced. The present study investigated the effect of dextromethorphan (DXM), an N-methyl-D-aspartate receptors (NMDARs) antagonist, on osteoporosis development. Main methods In order to examine the role of glutamate in bone metabolism, ovariectomized (Ovx) female Wistar rats were injected three times per week for 8 weeks with either saline, or 15 μg/kg of β-estrodiol, or DXM (40 mg/kg) intraperitoneally. Serum samples were collected every two weeks for measuring osteocalcin and C-terminal telopeptide of type I collagen (CTX-1) level. Rats were then sacrificed at week 8 and the femurs harvested for micro-CT scanning and mechanical strength. Key findings In saline-treated group, osteocalcin level significantly lower than that of sham-operated rats at 8 weeks after operation, while CTX-1 levels were not affected. Estrogen treatment, as a positive control, partially inhibited the Ovx-induced reduction of osteocalcin serum level. DXM injection prevented the Ovx-induced reduction of osteocalcin expression and significantly upregulated CTX-1 expression. The micro-CT scan showed that the bone volume density decreased significantly in DXM treated rats compared to the sham-operated rats. In the mechanical strength assay, the maximum failure load for DXM treatment was significantly lower than the other groups. Significance Treatment with DXM upregulated OB and OC markers in Ovx rats, however with a greater effect on the OC marker, and had no significant benefit on bone volume density or bone strength.",
keywords = "Dextromethorphan, Glutamate, Osteoblast, Osteoclast, Osteoporosis",
author = "Wu, {Jia Lin} and Tsai, {Wei Yuan} and Chen, {Jian Horng} and Wong, {Chih Shung}",
year = "2017",
month = "3",
day = "15",
doi = "10.1016/j.lfs.2017.01.011",
language = "English",
volume = "173",
pages = "145--149",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Dextromethorphan upregulates osteoblast and osteoclast activity but does not attenuate ovariectomy-induced osteoporosis

AU - Wu, Jia Lin

AU - Tsai, Wei Yuan

AU - Chen, Jian Horng

AU - Wong, Chih Shung

PY - 2017/3/15

Y1 - 2017/3/15

N2 - Aims Study on the in vivo regulatory role of glutamate in osteoblast (OB) and osteoclast (OC) differentiation is less advanced. The present study investigated the effect of dextromethorphan (DXM), an N-methyl-D-aspartate receptors (NMDARs) antagonist, on osteoporosis development. Main methods In order to examine the role of glutamate in bone metabolism, ovariectomized (Ovx) female Wistar rats were injected three times per week for 8 weeks with either saline, or 15 μg/kg of β-estrodiol, or DXM (40 mg/kg) intraperitoneally. Serum samples were collected every two weeks for measuring osteocalcin and C-terminal telopeptide of type I collagen (CTX-1) level. Rats were then sacrificed at week 8 and the femurs harvested for micro-CT scanning and mechanical strength. Key findings In saline-treated group, osteocalcin level significantly lower than that of sham-operated rats at 8 weeks after operation, while CTX-1 levels were not affected. Estrogen treatment, as a positive control, partially inhibited the Ovx-induced reduction of osteocalcin serum level. DXM injection prevented the Ovx-induced reduction of osteocalcin expression and significantly upregulated CTX-1 expression. The micro-CT scan showed that the bone volume density decreased significantly in DXM treated rats compared to the sham-operated rats. In the mechanical strength assay, the maximum failure load for DXM treatment was significantly lower than the other groups. Significance Treatment with DXM upregulated OB and OC markers in Ovx rats, however with a greater effect on the OC marker, and had no significant benefit on bone volume density or bone strength.

AB - Aims Study on the in vivo regulatory role of glutamate in osteoblast (OB) and osteoclast (OC) differentiation is less advanced. The present study investigated the effect of dextromethorphan (DXM), an N-methyl-D-aspartate receptors (NMDARs) antagonist, on osteoporosis development. Main methods In order to examine the role of glutamate in bone metabolism, ovariectomized (Ovx) female Wistar rats were injected three times per week for 8 weeks with either saline, or 15 μg/kg of β-estrodiol, or DXM (40 mg/kg) intraperitoneally. Serum samples were collected every two weeks for measuring osteocalcin and C-terminal telopeptide of type I collagen (CTX-1) level. Rats were then sacrificed at week 8 and the femurs harvested for micro-CT scanning and mechanical strength. Key findings In saline-treated group, osteocalcin level significantly lower than that of sham-operated rats at 8 weeks after operation, while CTX-1 levels were not affected. Estrogen treatment, as a positive control, partially inhibited the Ovx-induced reduction of osteocalcin serum level. DXM injection prevented the Ovx-induced reduction of osteocalcin expression and significantly upregulated CTX-1 expression. The micro-CT scan showed that the bone volume density decreased significantly in DXM treated rats compared to the sham-operated rats. In the mechanical strength assay, the maximum failure load for DXM treatment was significantly lower than the other groups. Significance Treatment with DXM upregulated OB and OC markers in Ovx rats, however with a greater effect on the OC marker, and had no significant benefit on bone volume density or bone strength.

KW - Dextromethorphan

KW - Glutamate

KW - Osteoblast

KW - Osteoclast

KW - Osteoporosis

UR - http://www.scopus.com/inward/record.url?scp=85013752340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013752340&partnerID=8YFLogxK

U2 - 10.1016/j.lfs.2017.01.011

DO - 10.1016/j.lfs.2017.01.011

M3 - Article

C2 - 28153746

AN - SCOPUS:85013752340

VL - 173

SP - 145

EP - 149

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

ER -